ACR 2022 Tweet by Robert B Chao, MD

Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression. New data presented at EULAR 2026 (POS0729) highlight the…

Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-T cell trials due to safety concerns, including deaths.Novartis has halted their cellular therapy trials with rap-cel (multiple autoimmune indications) because of 3…

In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullinated protein antibody …